Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

Leo Mascarenhas

Cedar-Sinai Health Sciences University, Los Angeles, CA

Steven G. DuBois

Catherine M. Albert

Stefan Bielack

Daniel Orbach

Siredo Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Institut Curie and University PSL, Paris, France

Noah Federman

Birgit Geoerger

Ramamoorthy Nagasubramanian

Yizhou Zhang

Julia Chisholm

Department of Pediatric Oncology, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, Surrey, United Kingdom

Soledad Gallego Melcon

Hiroaki Goto

Daniel A. Morgenstern

Cormac Owens

Our Lady's Children's Hospital, Dublin, Republic of Ireland

Alberto S. Pappo

St. Jude Children's Research Hospital, Memphis, TN

Sébastien Perreault

CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada

Johannes H. Schulte

University Children's Hospital Tübingen, Univerity Hospital Tübingen, Tübingen, Germany

Neerav Shukla

Christian Michel Zwaan

Natascha Neu

Chrestos GmbH, Essen, Germany

Vadim Bernard-Gauthier

Bayer HealthCare Pharmaceuticals, Inc., Mississauga, ON, Canada

Esther De La Cuesta

Cornelis M. van Tilburg

Theodore W. Laetsch

Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA